Abstract

A composition comprising CRH, CRH binding protein (CRH-BP), alpha-2 macroglobulin (A2M) and alpha-melanocyte stimulating hormone (alpha-MSH) for use in treatment of a medical condition selected from the list consisting of an ulcer or soft tissue damage.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
• A61K 38/34 - Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates to a CRH formulation and to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61K 38/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence
• A61P 17/06 - Antipsoriatics
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The present invention relates to a CRH formulation having improved stability/ efficacy. The improved CRH formulation is particularly suitable for treatment of various disorders. The invention also relates to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

The present invention relates to a CRH formulation having improved stability/ efficacy. The improved CRH formulation is particularly suitable for treatment of various disorders. The invention also relates to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61P 31/14 - Antivirals for RNA viruses

Goods & Services

(1) Pharmaceutical preparations and substances for human and veterinary use, namely, anti-inflammatory medication

Abstract

The invention relates to methods for reducing the plasma levels of TNF, VEGF, anti-inflammatory cytokines and chemokines. The invention also relates to methods and compositions for use in the treatment of a disorder characterised by abnormally high TNF and/or VEGF levels.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 13/00 - Drugs for disorders of the urinary system
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Methods of treatment of various non-demyelinating and demyelinating neural
disorders are provided, comprising administering a serum composition obtained
from a goat after challenge with an HIV immunogen, also called "Aimspro". Also

provided are methods of treatment of certain autoimmune disorders (e.g.
psoriasis) using such a composition.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• A61P 17/06 - Antipsoriatics
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 37/02 - Immunomodulators
• C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses